Chronic Myeloid Leukemia (CML) Treatment Global Market Report 2024

Description

Chronic myeloid leukemia (CML) treatment involves addressing the uncontrolled growth of abnormal white blood cells in the blood and bone marrow. These cells, known as myeloid cells, play a crucial role in fighting infections and maintaining the immune system.

The primary types of CML treatment include targeted therapy, chemotherapy, radiation therapy, splenectomy, and stem cell transplant. Targeted therapy is a cancer treatment approach that employs drugs to specifically target genes and proteins supporting the growth and survival of cancer cells. In the context of CML treatment, targeted therapy aims to identify and eliminate specific cancer cell types while minimizing damage to healthy cells. Various drugs, including tyrosine kinase inhibitors, antimetabolites, and others, are utilized in hospitals, clinics, and other healthcare settings for CML treatment. These medications are accessible through hospital pharmacies, retail pharmacies, and online pharmacy platforms.

The chronic myeloid leukemia (CML) treatment market research report is one of a series of new reports from The Business Research Company that provides chronic myeloid leukemia (CML) treatment market statistics, including the chronic myeloid leukemia (CML) treatment industry's global market size, regional shares, competitors with a chronic myeloid leukemia (CML) treatment market share, detailed chronic myeloid leukemia (CML) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic myeloid leukemia (CML) treatment industry. This chronic myeloid leukemia (CML) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic myeloid leukemia (cml) treatment market size has grown strongly in recent years. It will grow from $7.73 billion in 2023 to $8.18 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth observed in the historical period can be attributed to several factors, including heightened awareness and early detection practices, positive outcomes from clinical trials, advancements in the development of targeted therapies, the presence of patient advocacy and support groups, and the ongoing development of healthcare infrastructure. These elements collectively contributed to the progress and improvement in the landscape of chronic myeloid leukemia (CML) treatment during the historic period.

The chronic myeloid leukemia (cml) treatment market size is expected to see strong growth in the next few years. It will grow to $10.4 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The anticipated growth in the forecast period can be attributed to the adoption of personalized medicine approaches, the development of combination therapies, improved patient access to novel treatments, government policies supporting orphan drugs, and the overall increase in healthcare expenditure. Key trends in the forecast period include global collaboration in research efforts, the widespread adoption of telemedicine and remote monitoring, advancements in next-generation tyrosine kinase inhibitors (TKIs), and the implementation of treatment optimization strategies. These trends collectively contribute to the evolving landscape of chronic myeloid leukemia (CML) treatment.

The projected rise in the incidence and prevalence of chronic myeloid leukemia (CML) is anticipated to be a significant driver of growth in the chronic myeloid leukemia (CML) treatment market. This type of leukemia, also known as chronic myelogenous leukemia, profoundly impacts the bone marrow and blood by causing an excessive production of immature myeloid cells. Treatment for chronic myeloid leukemia is crucial in slowing down its progression and preventing its advancement to more severe stages. For instance, based on data from the American Society of Clinical Oncology in March 2023, the United States expects a substantial number of individuals, around 35,730, to be diagnosed with multiple myeloma. Furthermore, approximately 12,590 deaths due to this disease are anticipated in 2023. These statistics underscore the pressing need for effective treatments, thereby driving the growth of the chronic myeloid leukemia (CML) treatment market.

The advent of personalized medicine has significantly contributed to the expansion of the chronic myeloid leukemia (CML) treatment market. Personalized medicine involves tailoring treatment plans and decision-making processes for patients based on a comprehensive understanding of their genetic makeup. In the context of CML, this approach enables the identification of specific molecular targets, notably the BCR-ABL fusion gene, allowing for a precise comprehension of the genetic irregularities driving the disease in individual patients. This understanding paves the way for early interventions and the implementation of personalized preventive measures. For example, the Swedish Government's investment of SEK 220 million ($21.15 million) in the Genomic Medicine Sweden (GMS) national infrastructure is aimed at integrating precision medicine into the country's healthcare system. Additionally, the rising demand for personalized medicines, as highlighted by the Personalized Medicine Coalition (PMC), indicates that these medicines could constitute 34% of new drug approvals by the US Food and Drug Administration in 2022, further supporting the anticipated growth of the chronic myeloid leukemia (CML) treatment market.

Product innovation stands as a pivotal trend shaping the landscape of the chronic myeloid leukemia (CML) treatment market. Companies engaged in this sector are actively embracing novel technologies to fortify their market presence. For instance, Novartis, a Switzerland-based pharmaceutical giant, achieved FDA approval for Scemblix (asciminib) in October 2021, marking a significant milestone as the first FDA-approved treatment for chronic myeloid leukemia. Scemblix operates by binding to the ABL myristoyl pocket, catering to patients facing resistance or intolerance to existing TKI therapies. Impressively, Scemblix demonstrated superior performance compared to Bosulif (bosutinib) over 24 weeks, boasting a higher major molecular response (MMR) rate at 25% versus 13% and significantly lower discontinuation rates due to adverse effects at 7% versus 25%.

Strategic partnerships and collaborations are key focal points for companies aiming to broaden their product spectrum and geographical footprint. For instance, Xspray Pharma, a Sweden-based biotechnology company, forged a partnership with EVERSANA, a US-based life sciences entity, in February 2023. This collaboration aims to support the US launch and commercialization of Dasynoc (XS004), a promising treatment for chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL). Though pending FDA approval and contingent upon legal conditions, Dasynoc signifies a novel treatment option anticipated to penetrate the lucrative $3.5 billion Tyrosine Kinase Inhibitors market in the United States. Leveraging EVERSANA's specialized commercialization team entrenched in the oncology market, Xspray aims for a tailored and effective approach to introduce Dasynoc, with a projected launch slated for the latter half of 2023. This strategic move holds the promise of significantly enhancing treatment options for CML and ALL patients within the US market.

In August 2022, the US-based multinational pharmaceutical company Bristol Myers Squibb successfully acquired Turning Point Therapeutics for $4.1 billion. This strategic acquisition provides Bristol Myers Squibb with access to Turning Point Therapeutics' pipeline of experimental drugs, notably repotrectinib, designed to target prevalent mutations associated with oncogenesis. Turning Point Therapeutics, based in the US, specializes in the development of precision medicines for cancer and other diseases, including tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia (CML).

Major companies operating in the chronic myeloid leukemia (cml) treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Hospira Inc., Otsuka Pharmaceutical Co. Ltd., Incyte Corporation, Cipla Limited, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Innovent Biologics Inc., Glenmark Pharmaceuticals Limited, Il-Yang Pharmaceutical Co. Ltd., Accord Healthcare Inc., ARIAD Pharmaceuticals Inc., Stragen Pharma SA, Orca Bio, Bio-Path Holdings Inc.

North America was the largest region in the chronic myeloid leukemia (CML) treatment market in 2023. The regions covered in the chronic myeloid leukemia (cml) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chronic myeloid leukemia (cml) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic myeloid leukemia (CML) treatment market includes revenues earned by entities by providing targeted therapy with tyrosine kinase inhibitors (TKIs). The chronic myeloid leukemia market includes Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Asciminib. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Myeloid Leukemia (CML) Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic myeloid leukemia (cml) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic myeloid leukemia (cml) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic myeloid leukemia (cml) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Type: Targeted Therapy; Chemotherapy; Radiation Therapy; Splenectomy; Stem Cell Transplant
2) By Drug Type: Tyrosine Kinase Inhibitors; Antimetabolites; Other Drug Types
3) By Application: Hospitals; Clinic; Other Applications
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r13593

1. Executive Summary

2. Chronic Myeloid Leukemia (CML) Treatment Market Characteristics

3. Chronic Myeloid Leukemia (CML) Treatment Market Trends And Strategies

4. Chronic Myeloid Leukemia (CML) Treatment Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Chronic Myeloid Leukemia (CML) Treatment Market Size and Growth

5.1. Global Chronic Myeloid Leukemia (CML) Treatment Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Chronic Myeloid Leukemia (CML) Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Chronic Myeloid Leukemia (CML) Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Chronic Myeloid Leukemia (CML) Treatment Market Segmentation

6.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Targeted Therapy
Chemotherapy
Radiation Therapy
Splenectomy
Stem Cell Transplant
6.2. Global Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Tyrosine Kinase Inhibitors
Antimetabolites
Other Drug Types
6.3. Global Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Clinic
Other Applications
6.4. Global Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

7. Chronic Myeloid Leukemia (CML) Treatment Market Regional And Country Analysis

7.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Chronic Myeloid Leukemia (CML) Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market

8.1. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Chronic Myeloid Leukemia (CML) Treatment Market

9.1. China Chronic Myeloid Leukemia (CML) Treatment Market Overview
9.2. China Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Chronic Myeloid Leukemia (CML) Treatment Market

10.1. India Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Chronic Myeloid Leukemia (CML) Treatment Market

11.1. Japan Chronic Myeloid Leukemia (CML) Treatment Market Overview
11.2. Japan Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Chronic Myeloid Leukemia (CML) Treatment Market

12.1. Australia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Chronic Myeloid Leukemia (CML) Treatment Market

13.1. Indonesia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Chronic Myeloid Leukemia (CML) Treatment Market

14.1. South Korea Chronic Myeloid Leukemia (CML) Treatment Market Overview
14.2. South Korea Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market

15.1. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market Overview
15.2. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Chronic Myeloid Leukemia (CML) Treatment Market

16.1. UK Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Chronic Myeloid Leukemia (CML) Treatment Market

17.1. Germany Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Chronic Myeloid Leukemia (CML) Treatment Market

18.1. France Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Chronic Myeloid Leukemia (CML) Treatment Market

19.1. Italy Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Chronic Myeloid Leukemia (CML) Treatment Market

20.1. Spain Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market

21.1. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market Overview
21.2. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Chronic Myeloid Leukemia (CML) Treatment Market

22.1. Russia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Chronic Myeloid Leukemia (CML) Treatment Market

23.1. North America Chronic Myeloid Leukemia (CML) Treatment Market Overview
23.2. North America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Chronic Myeloid Leukemia (CML) Treatment Market

24.1. USA Chronic Myeloid Leukemia (CML) Treatment Market Overview
24.2. USA Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Chronic Myeloid Leukemia (CML) Treatment Market

25.1. Canada Chronic Myeloid Leukemia (CML) Treatment Market Overview
25.2. Canada Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Chronic Myeloid Leukemia (CML) Treatment Market

26.1. South America Chronic Myeloid Leukemia (CML) Treatment Market Overview
26.2. South America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Chronic Myeloid Leukemia (CML) Treatment Market

27.1. Brazil Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Chronic Myeloid Leukemia (CML) Treatment Market

28.1. Middle East Chronic Myeloid Leukemia (CML) Treatment Market Overview
28.2. Middle East Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Chronic Myeloid Leukemia (CML) Treatment Market

29.1. Africa Chronic Myeloid Leukemia (CML) Treatment Market Overview
29.2. Africa Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Chronic Myeloid Leukemia (CML) Treatment Market Competitive Landscape And Company Profiles

30.1. Chronic Myeloid Leukemia (CML) Treatment Market Competitive Landscape
30.2. Chronic Myeloid Leukemia (CML) Treatment Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. F. Hoffmann-La Roche Ltd.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Merck & Co. Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. AbbVie Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Bayer AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Chronic Myeloid Leukemia (CML) Treatment Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. Bristol-Myers Squibb Company
31.3. AstraZeneca plc
31.4. Takeda Pharmaceutical Company Limited
31.5. Amgen Inc.
31.6. Viatris Inc.
31.7. Teva Pharmaceutical Industries Ltd.
31.8. Eisai Co. Ltd.
31.9. Fresenius Kabi AG
31.10. Sun Pharmaceutical Industries Ltd.
31.11. Hospira Inc.
31.12. Otsuka Pharmaceutical Co. Ltd.
31.13. Incyte Corporation
31.14. Cipla Limited
31.15. Dr. Reddy's Laboratories Ltd.

32. Global Chronic Myeloid Leukemia (CML) Treatment Market Competitive Benchmarking

33. Global Chronic Myeloid Leukemia (CML) Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Chronic Myeloid Leukemia (CML) Treatment Market

35. Chronic Myeloid Leukemia (CML) Treatment Market Future Outlook and Potential Analysis

35.1 Chronic Myeloid Leukemia (CML) Treatment Market In 2028 - Countries Offering Most New Opportunities
35.2 Chronic Myeloid Leukemia (CML) Treatment Market In 2028 - Segments Offering Most New Opportunities
35.3 Chronic Myeloid Leukemia (CML) Treatment Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer